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hCG-secreting malignancies — diagnostic 
pitfalls
ABSTRACT
We present a case of a 34-year-old male patient referred to our Uro-oncology Department with a suspicion of 
a metastatic germ cell tumour, owing to enlarged left testicle and elevated b-hCG concentration (39 mIU/mL). 
Impaired performance status caused by extensive pulmonary and liver metastases, accompanied by significant 
lymphadenopathy, necessitated prompt management. However, a testicular tumour was excluded on ultrasound 
imaging; a hydrocele only was found. The b-hCG concentration was not increasing (37 mIU/mL). We found a diag-
nosis of an extragonadal germ cell tumour doubtful, and a liver biopsy was performed. Due to the patient’s quick 
deterioration, we decided to commence pre-phase chemotherapy with cisplatin and etoposide, which resulted 
in a significant clinical improvement. The pathological examination, along with immunoassays, revealed undif-
ferentiated cholangiocarcinoma, and the patient continued chemotherapy with a biliary tract cancer regimen, 
i.e. cisplatin and gemcitabine. Unfortunately, the clinical response was short-lived; the disease progressed, the 
patient was offered best supportive care and died two months after the diagnosis.
The case underpins the literature review with respect to differential diagnosis of an elevated hCG concentration. 
In particular, we discuss ectopic secretion in non-trophoblastic and non-germinal malignancies and the causes 
of false positive assays.
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Introduction
Human chorionic gonadotropin (hCG) is a glyco-
protein hormone produced by trophoblast during preg-
nancy. In oncology, it serves as a marker of gestational 
trophoblastic disease (GTD) and germ cell tumours 
(GCT). Additionally, hCG in its various forms has been 
found in tissues of non-trophoblastic and non-germinal 
malignancies [1], where it promotes tumour growth and 
invasion. Serum hCG reactivity may therefore pose 
diagnostic difficulties.
GCTs account for the majority of malignancies 
in young men. Usually testicular in origin, they may 
also develop in the retroperitoneum, mediastinum, 
or cerebrum, along the body’s midline. Because the 
cure rate and prognosis are excellent even in the 
metastatic cases, the issues of prompt diagnosis and 
adequate treatment are of utmost importance [2, 3]. In 
selected patients, the diagnosis of GCT can be solely 
established on the basis of elevated tumour marker 
concentrations, i.e. a-foetoprotein (AFP) and/or 
b-hCG [3]. Therefore, it is crucial to be aware of and 
avoid pitfalls that may mislead a physician and postpone 
the correct diagnosis. 
We present a case of hCG-secreting cholangiocarci-
noma, referred to our centre with a suspicion of GCT. 
Possible scenarios of paraneoplastic secretion and false 
positive hCG assays are also reviewed.
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Case report
A 34-year-old male patient was admitted to a res-
piratory medicine centre with a four-month history of 
persistent, unproductive cough and dyspnoea, first on 
exertion and then at rest. A chest computed tomography 
(CT) scan revealed disseminated bilateral lung nod-
ules, thickened bronchial walls, ground-glass opacity, 
enlarged heart, pericardial effusion (14 mm), as well 
as fractured sternum and 2nd left rib. Abdominal and 
pelvic CT scans showed abdominal and retroperitoneal 
lymphadenopathy (38 mm and 17 mm, respectively), 
multiple liver metastases (max. 40 mm), and agenesis 
of the left kidney. No abnormalities apart from a max-
illary sinus polyp were found on CT scan of the head. 
Moreover, the patient gave a six-month history of left 
testicle enlargement; on ultrasound (US) the picture was 
characteristic of a testicular hydrocele, but the presence 
of a tumour could not be ruled out. Serum hCG con-
centration of 39 mIU/mL (normal < 5 mIU/mL) gave 
rise to a suspicion of a germ cell tumour. At this stage, 
in February 2019, the patient was referred to our centre.
On admission, he presented with cough and dysp-
noea, ECOG performance status 2, and pulse oximetry of 
88% (94% on O2). hCG concentration was 37 mIU/mL 
(normal < 5 mIU/mL), and a-foetoprotein (AFP) and 
lactate dehydrogenase (LDH) concentrations were 
within normal limits. Blood count and chemistry as well 
as coagulation parameters showed no important abnor-
malities. Scrotal US revealed a left testicular hydrocele 
(15 mL) and no suspicious tumours. Haemodynamically 
insignificant pericardial effusion and normal contractil-
ity of cardiac muscle (left ventricle ejection fraction of 
65%) were found on echocardiography.
The case was presented at a multi-disciplinary clini-
cal meeting. Due to a relatively low increase in hCG 
concentration together with massive metastases, the 
diagnosis of an extragonadal germ cell tumour was du-
bious. We agreed that a pathological diagnosis should 
be established; one of the liver metastases was chosen 
for a core biopsy.
Once the biopsy had been performed, we decided to 
commence pre-phase chemotherapy due to the patient’s 
steady clinical deterioration. Cisplatin (20 mg/m2) and 
etoposide (100 mg/m2) were administered on days 1–2, 
with prophylaxis of the acute tumour lysis syndrome 
(ATLS) and thromboprophylaxis. The pre-phase re-
sulted in a rapid improvement with respect to dyspnoea 
and pulse oximetry (94–98% with no O2 supply).
The pathology report revealed an undifferentiated 
(G3) adenocarcinoma with high mitotic activity. Immu-
nostaining was as follows: CKAE 1/3 (+), CK19 (+), 
CK7 (–), CK20 (–), SALL4 (–), PLAP (–), b-hCG (–), 
CD 30 (–), CDX2 (–). It was characteristic of cholan-
giocarcinoma (highly-aggressive type? — untypical lack 
of CK7 expression) or gastric carcinoma (Figures 1–3). 
Germ cell tumours were ultimately excluded. On gas-
Figure 2. Undifferentiated cholangiocarcinoma, CK19 (+)
Figure 3. Undifferentiated cholangiocarcinoma, CK7 (–)
Figure 1. Undifferentiated cholangiocarcinoma, HE staining, 
mag. 200 ×
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troscopy, gastric and duodenal inflammatory lesions 
were biopsied; chronic gastritis/duodenitis was diag-
nosed pathologically.
This led to the final diagnosis of cholangiocarcinoma 
(TNM 8th edition: cTx cN1 pM1; clinical stage IV). The 
chemotherapy regimen was changed to GP (gemcitabine 
800–1000 mg/m2 days 1, 8 and cisplatin 30 mg/m2 days 
1, 8; to be repeated every three weeks). Only two cycles 
were administered. Although substantial, the clinical 
improvement was short-lived. Dyspnoea recurrence and 
performance status decline (ECOG 4) was observed. 
With best supportive care, the patient died two months 
after the diagnosis.
Discussion
Germ cell tumours (GCT), however rare, account 
for the most common malignancies in males aged 
15–40 years [2]. The highest incidence rates are observed 
in developed countries (11.8 per 100,000 in Norway) [3]. 
Therefore, given the patient’s age, clinical presentation, 
and an elevated hCG concentration, the suspicion of 
GCT in the patient described was justified. However, 
once a testicular tumour was ruled out on US, the prob-
ability of GCT decreased, because only 5% of GCT are 
extragonadal (EGGCT) [2]. Importantly, EGGCTs typi-
cally arise in the body’s mid-line, e.g. retroperitoneum, 
mediastinum, or cerebrum [2]. This, in turn, was not 
the case in our patient. Massive pulmonary and liver 
metastases were accompanied by relatively small retrop-
eritoneal lymphadenopathy (17 mm) and no mediastinal 
lymphadenopathy. Still, such a presentation could have 
resulted from an aggressive non-seminomatous GCT, 
e.g. choriocarcinoma, a histological component more 
likely to give visceral metastases with a small or even 
burned-out primary testicular tumour. In this case, 
however, the hCG concentration would have been much 
higher, corresponding with the tumour burden. Overall, 
we considered the possible diagnosis of GCT doubtful 
and decided on the liver biopsy. 
Some GCT patients are not fit enough to start treat-
ment with full doses of combination chemotherapy. This 
usually stems from a massive tumour volume with sig-
nificantly elevated marker concentrations and a high risk 
of bleeding (e.g. choriocarcinoma) as well as impaired 
performance status and organ dysfunction. To avoid 
fatal complications, a pre-phase chemotherapy should 
be administered, for instance 2–3 days of cisplatin and 
etoposide or single-agent low-AUC carboplatin. Once 
the patient has improved, full-dose chemotherapy must 
be started [3]. Understandably, there are scarce data 
available on this topic. We decided to administer such 
induction treatment to our patient, without liver biopsy 
results, given his rapidly deteriorating status. In case 
of GCT diagnosis, we would have continued with four 
cycles of standard BEP or VIP chemotherapy. Even 
with another tumour histology, which finally proved the 
case, cisplatin and etoposide would have been likely to 
decrease the tumour volume before adapting further 
treatment to the pathology outcome.
hCG is a protein composed of two subunits: a, com-
mon to all glycoprotein hormones; and b, responsible 
for its specific structure and activity [1]. Different forms 
of the hormone are encountered in vivo, e.g. the native 
hCG, hyperglycosylated hCG (hyp-hCG), nicked-hCG, 
or the free b-subunit. Apart from the role played in 
pregnancy, hCG is capable of promoting angiogenesis, 
supressing macrophage activity, blocking apoptosis 
(hyp-hCG), promoting choriocarcinoma invasion, as 
well as enhancing malignant transformation, growth, and 
invasion of non-trophoblastic malignancies (b-subunit 
and hyp-hCG) [1]. The hormone variants may be de-
tected both in serum and cancer tissue.
Elevated in all cases of gestational trophoblastic 
disease, hCG serves as an ideal marker, contributing 
to diagnosis, treatment monitoring, and follow-up. 
hCG-secreting germ cell tumours account for 40–50% 
of non-seminomas and 15–20% of seminomas tumours 
[1]. In non-seminomas tumours, the hCG concentration 
is one of the prognosis factors.
Other malignancies very often express and secret 
hCG [4–21]; the protein is synthesised either by the 
whole tumour cell population or by a subclone of undif-
ferentiated cells. Most frequently, the b-subunit is pro-
duced [1]. Many authors point out that hCG synthesis is 
a factor of poor prognosis. Examples of non-gestational 
and non-germinal neoplasms secreting hCG are shown 
in Table 1. Many others, however, have been reported 
in the literature. 
Truly elevated serum hCG concentrations may be 
observed in hypogonadal men [22] and postmenopausal 
women [23]. The pituitary gland, normally secreting 
small amounts of the hormone, is stimulated to hCG 
production in the event of a marked decrease in sex hor-
mones concentrations. A two-week hormone replace-
ment therapy should suffice to assess whether this is the 
case in our patient [23, 24]. Another reason, sometimes 
difficult to elicit from the patient, is self-administering 
of hCG. Male athletes who abuse anabolic steroids 
withdraw them at intervals and switch to hCG in order 
to stimulate endogenous testosterone production and 
prevent testicular atrophy [25].
In oncological daily practice, it is worth remembering 
that markers may be secreted from the tumour mass af-
ter chemotherapy initiation, i.e. during the first cycle, or 
even from necrotic tissues after the completion of treat-
ment [26]. Germ cell tumour patients with persistent 
elevated markers after first-line chemotherapy should be 
closely followed up and scheduled for prompt residual 
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tive hCG assay in the urine sample may explain the false 
positivity of the serum [28]. However, even in case of 
true positive serum, the hCG concentration in urine may 
be too low to be detected [24]. 
Reports of false positive hCG assays due to cannabi-
noid use can also be found in the literature [29], although 
not confirmed by some authors [30]. Nevertheless, his-
tory taking should cover this aspect as well. 
In our patient, hCG immunostain in the liver biopsy 
specimen was notably negative despite serum positivity. 
This may have been due to a small sample or the fact that 
only a subclone of cancer cells produced b-hCG. Another 
explanation may be rapid secretion of hCG outside the 
cancer cells and into circulating blood, hence leaving an 
undetectable amount in the cytoplasm. Low sensitivity 
of the assays used may have added to the outcome [15].
The differential diagnosis of GCT, other malig-
nancies, and false-positive hCG assays is of utmost 
importance. In selected cases of substantial tumour 
burden, extensive visceral metastases, and impending 
organ failure, the diagnosis of GCT may be established 
on the basis of unequivocally elevated serum markers 
(hCG, AFP). This may pose serious difficulties because 
there is no objective concentration cut-off value. In 
the literature reviewed, the highest paraneoplastic 
hCG result was 7660 mIU/mL [4]. On the other hand, 
a typical clinical presentation, along with very high 
GCT marker concentrations and a need for immediate 
chemotherapy, sanctions treatment initiation without 
histological confirmation.
In conclusion, the subtleties of GCT marker inter-
pretation, given the expected radical treatment outcome, 
support referring such patients to high-volume centres 
of excellence [2, 3].
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